If simvastatin is prescribed to a patient with intermediate SLCO1B1 function as a heterozygous variant, there is an increased risk for developing simvastatin-associated myopathy; such cases might require a lower starting dose of simvastatin or another statin agent (Ramsey et al., 2014). Here, SLCO1B1 is linked to myopathy.